Campral is a prescription medication used to support long-term abstinence in individuals with alcohol use disorder. Its therapeutic purpose is to reduce the risk of relapse by helping to restore normal brain activity after prolonged alcohol consumption. The drug functions by acting as an antagonist at nmda excitatory receptors and a modulator of gaba inhibitory receptors. This dual action dampens excessive excitatory signaling and enhances inhibitory tone, thereby decreasing alcohol cravings. Campral is administered orally in tablet form and works continuously without the need for titration or monitoring of blood levels. The overall effect is a more stable neurochemical environment that supports sustained recovery when combined with psychosocial support.

Campral is the brand name for acamprosate, a medication approved for the maintenance of abstinence in individuals with alcohol use disorder. Pharmacodynamically it acts as a competitive antagonist at metabotropic glutamate receptors and modulates the activity of nmda receptors, thereby restoring the balance of excitatory neurotransmission disrupted by chronic alcohol exposure. Pharmacokinetically it is uniformly absorbed after oral administration, reaches peak plasma concentrations within a few hours, and is eliminated primarily unchanged by the kidneys with a half-life of approximately 3 to 5 hours. The therapeutic purpose of the drug is to reduce craving for alcohol and to attenuate the physiological discomfort associated with withdrawal, supporting long-term sobriety when combined with counseling and support. Its mechanism of action involves enhancing inhibitory gabaergic signaling indirectly while dampening the hyperglutamatergic state that characterizes alcohol-induced neuroadaptation, leading to decreased rewarding effects of alcohol. By normalizing glutamatergic neurotransmission and stabilizing neuronal excitability, Campral helps sustain abstinent behavior without producing sedation or significant abuse potential.

Campral (acamprosate) is used to help maintain abstinence from alcohol after detoxification. Some people experience abdominal discomfort, nausea, or diarrhea when taking the medication. Headaches and dizziness are also reported side effects in clinical studies. Insomnia or difficulty sleeping may occur, especially during the initial adjustment period. Fatigue and reduced mental alertness can be observed in certain individuals. Rarely, allergic skin reactions such as rash or itching have been documented. Mood changes including depression or anxiety have been noted in some patients. Most side effects are mild to moderate and often improve as the body adapts to the drug.

Common side effects of Campral include headache, nausea, and dizziness. Some individuals may experience insomnia or vivid dreams. Weight loss has been reported in a small number of patients. Allergic reactions such as rash or itching can occur. Rarely, liver enzyme elevations have been observed during treatment. These effects are generally mild and reversible upon discontinuation.